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Introduction
 Human epidydimis secretory protein 4 is an 11-
kDa protein, which is localized on chromosome 20q12 
(Schummer et al., 1999). For the first it was identified 
in epidydimis epithelium and its function was initially 
associated with the maturation of sperm involved in 
protease inhibition (Kirchhoff et al., 1998). Human 
epidydimis secretory proteins in the cell can be found 
in the cytoplasm perinucleary as endoplasmatic network 
structure. There is glycosylation and release of the HE4 
in extracellular environment from ovarian cancer cells 
(Drapkin et al., 2005). Ovarian cancer associated antigen 
CA125 is increased in 40-50% of early stage ovarian 
cancer patients (Rosen et al., 2005), but there have been 
documented that human epidydimis secretory protein 4 
is increased in 82.7-90.0% cases of early stage ovarian 
cancers (Havrilesky et al., 2008), moreover, HE4 is 
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Abstract
 Objective: To analyze differential diagnostic accuracy of urinary human epidydimis secretory protein 4 (HE4)
in patients with ovarian tumors. Materials and methods: In the case-control study 23 patients with ovarian 
cancer, 37 patients with benign ovarian tumors and 18 women in the control group were included. Serum CA125 
values and urinary concentrations of HE4were assessed quantitatively. Urinary creatinine concentrations and 
glomerular filtration rate were also determined and used to calculate ratios to HE4. Results: Higher urinary 
HE4 concentrations were observed in patients with late stage ovarian cancer (p=0.001) and also in patients with 
early stage ovarian cancer when compared to patients with benign ovarian tumors (p=0.044). On analysis where 
all ovarian cancer patients were included, higher diagnostic accuracy was observed with calculated ratio of 
HE4 to glomerular filtration rate (GFR) to unchanged urinary HE4 concentrations -AUC 0.861 vs. 0.858. When 
discriminatory accuracy was calculated for urinary HE4/GFR ratio and unchanged urinary HE4 concentrations, 
the last demonstrated a higher area under the curve - 0.701 vs. 0.602. The urinary HE4/creatinine ratio had 
lower discriminatory characteristics than unchanged concentrations of urinary HE4. However, HE4 serum 
concentration was more accurate for discrimination of patients with benign and malignant ovarian tumors when 
compared to urinary HE4 and CA125 in sera (AUCs were 0.868 for serum HE4 and 0.856 and 0.653 for urinary 
HE4 and CA125, respectively). Conclusions: Ovarian cancer patients have higher urinary concentrations of 
human epidydimis secretory protein 4 than patients with benign ovarian tumors. Urinary HE4 has comparable 
discriminatory accuracy with serum HE4 for benign and malignant ovarian tumors and can be recommended 
as a non-invasive ovarian cancer risk assessment method. 
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elevated in more than 50% of cases when the CA125 assay 
values are within the normal range (Moore et al., 2007). 
There are several explanations why human epidydimis 
secretory protein 4 is more sensitive in comparison to 
CA125. HE4 is a high molecular weight glycoprotein with 
an approximate molecular mass 80 kDa, but its secreted 
form is a 11 kDa protein, that explains an earlier release 
of biomarker in the blood stream (Schummer et al., 1999). 
Earlier appearance of human epidydimis secretory protein 
4 in the serum in case of early stage ovarian cancer is 
likely to be associated with a simpler mechanism for its 
release (Boshell et al., 1992; Ligtenberg et al., 1992; Yin 
et al., 2001).
 The role of HE4 in the human body is explained only 
partly. Human epidydimis secretory protein 4 promotes 
tumor cell adhesion and motility. In cellular level HE4 
contributes to epidermal growth factor receptor activation 
and adhesion molecule expression on the cell surface. 
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HE4 expression is associated with cell proliferation and 
migration via mitogen activated protein kinase path (Guo 
et al., 2011). Hellström et al. was one of the first who have 
reported an increased concentration of HE4 in the sera of 
ovarian cancer patients (Hellström et al., 2003).
 More expressed human epidydimis secretory protein 
4 has been detected in tissues of serous and endometrioid 
ovarian cancers (Drapkin et al., 2005). Lower serum HE4 
concentrations have been observed in patients with early 
stage ovarian cancer. Similarly, women with borderline 
ovarian tumors have lower serum HE4 concentrations 
than patients with invasive ovarian cancer. No differences 
have been identified in serum concentrations of HE4 in 
patients with various degrees of morphological grade 
ovarian cancers (van Gorp et al., 2011). Hellström et al. 
demonstrated that the combination of HE4 and CA125 
assay provides higher ovarian cancer diagnostic sensitivity 
and specificity than each biomarker alone (Hellström 
et al., 2003). Relatively high diagnostic sensitivity and 
specificity of HE4 can be explained by the fact that the 
biomarker is not elevated in many benign gynecologic 
diseases when CA125 levels are increased (Hellström et 
al., 2003; Moore et al., 2008). Patients with endometrioid 
ovarian cysts and endometriosis have increased serum 
CA125 values, whereas the concentration of HE4 is not 
increased (Huhtinen et al., 2009).
 Objective of the study was to analyze differential 
diagnostic accuracy of urinary human epidydimis 
secretory protein 4 in patients with benign and malignant 
ovarian tumors.
Materials and Methods
 In the case-control study 23 patients with ovarian 
cancer, 37 patients with benign ovarian tumors and 18 
women in the control group were included.
 Blood samples were taken before surgery in two 6-ml 
vaccutainers with coagulation activator. Sera and urine 
for the women included in the control group were taken 
during outpatient visits. According to the manufacturer’s 
recommendations vaccutainers were shaked, left to stay 
for 60 minutes in a vertical position and then centrifuged 
for 10 minutes with 1300 rpm. After serum separation, 
they were transferred to cold storage at -80 degrees 
Celsius. Before the anticipated surgery urine samples were 
collected in special, sterile urine collection containers. 
Urine samples were stored for 60-120 minutes at room 
temperature, then divided into four tubes of 0.5 ml each 
and transferred to the freezer for long-term storage at -80 
degrees Celsius.Each defrost serum and urine sample was 
used only once.
 Serum CA125 assay values were assessed using 
the automated Abbott Architect analyzer 2000 and the 
appropriate reagents Abbott ARCHITECT CA125 assay 
values II. ARCHITECT serum dilution buffer was used 
to determine the concentrations of CA125 assay values 
0-10000 U/ml range. Human epidydimis secretory protein 
4 quantitatively in urine was determined using automated 
analyzer Abbott Architect and appropriate reagent kits 
(Abbott Diagnostics). Urinary samples were diluted 1:100 
before analysis of HE4 concentration. Urinary creatinine 
concentrations were determined and used to calculate 
human secretory protein epidydimis 4 and creatinine ratio 
in urine.
Statistical processing
 To characterize the study groups descriptive statistics 
was applied. Compliance with the normal (Gaussian) 
distribution of the biomarker concentrations in the study 
groups were tested with the Shapiro-Wilk test. Data 
normalization was performed using the natural logarithm 
function in cases where the concentrations of biomarkers 
did not meet the normal distribution. Differences of 
mean biomarker concentrations in the study groups were 
determined using t-tests and 95% confidence interval (CI). 
Diagnostic accuracy of biomarkers was compared using 
area under the curve (AUC). Statistical and graphical data 
processing was performed using the professional statistical 
software SPSS 20.00 (SPSS Inc., USA).To evaluate 
sensitivity and specificity of urinary HE4 comparison 
to serum HE4 and Ca125 diagnostic accuracy was 
performed. Separately ovarian cancer diagnostic accuracy 
was calculated for HE4 concentration and glomerular 
filtration rate ratio and also to HE4 and urinary creatinine 




 Patients with ovarian cancer, especially, of late stage 
had the highest mean urinary concentrations of human 
epidydimis secretory protein 4 (Table 1.) 
 Higher urinary HE4 concentrations were observed 
for patients with late stage ovarian cancer and also for 
patients with early stage ovarian cancer when compared 
to patients with benign ovarian tumors (Table 2.).
 Patients with malignant ovarian tumors had higher 
mean concentrations of urinary and also serum HE4 than 
the rest of the study group patients (Figure 1).
 Glomerular filtration rate was similar (p=0.096) 
although patients with benign and particularly with 
malignant ovarian tumors had a tendency to lower 
filtration rate (77.06±28.07 mL/min and 64.82±12.95 mL/
Table 1. Mean Urinary Concentrations of Human 
Epidydimis Secretory Protein 4 in Study Groups
Study groups Log transformed mean urinary
  HE4 concentrations
  (pmol/l±SD)
Late stage ovarian cancers (III/IV; n=12) 11.276 ± 1.145
Early stage ovarian cancers (I/II; n=11) 9.734 ± 1.053
Patients with benign ovarian tumors (n=37) 9.105 ± 0.970
Control group (n=18) 8.640 ± 0.732
Table 2. Mean Urinary Concentrations of Human 
Epidydimis Secretory Protein 4 in Study Groups
Study groups p (t-test)
Late stage ovarian cancers (III/IV) vs. early stage ovarian cancers (I/II) 0.001
Early stage ovarian cancers (I/II) vs. benign ovarian tumor 0.044
Benign ovarian tumors vs. control  0.093
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Figure 2. Glomerular Filtration Rate in the Ovarian 
Cancer Diagnostic Accuracy of Urinary He4 (All 
Ovarian Cancer Patients Included in the Analysis 
Irrespective of Stage). 
Figure 3. Comparison of Diagnostic Accuracy 
for Urinary He4 and Urinary He4/Creatinine 
Concentration in Discrimination of Ovarian Cancer 
Patients. 
Figure 4. Accuracy of Urinary He4 Concentration 
and Urinary He4/Glomerular Filtration Rate Ratio 
in Early Stage Ovarian Cancer (Stage I/Ii) Diagnostic.
Figure 5. Ovarian Cancer Diagnostic Accuracy of 
Serum and Urinary He 4 in Comparsion to Ca125. 
Figure 1. Mean Urinary and Serum HE4 Concentrations 
in the Study Groups. 
in ovarian cancer patients (9.57±0.82 pmol/L) when 
compared to patients with benign ovarian tumors 
(8.94±0.94 pmol/L) and women in the control group 
(9.08±0.77 pmol/L).
 Higher ovarian cancer diagnostic accuracy was 
observed when there was calculated ratio between urinary 
human epidydimis secretory protein 4 concentration and 
glomerular filtration rate (Figure 2).
Ovarian tumor discriminatory accuracy for unchanged 
concentrations of human epidydimis secretory protein 4 
and HE4 and urinary creatinine ratio was calculated only in 
44 patients (11 ovarian cancer patients and 33 patients with 
benign ovarian tumors), therefore values for area under 
the curve are higher than in other ROC curves. Unchanged 
concentrations of urinary human epidydimis secretory 
protein 4 revealed higher accuracy in discrimination of 
ovarian cancer patients in comparison to urinary HE4 and 
urinary creatinine ratio (Figure 3).
Higher diagnostic accuracy of early stage ovarian 
cancer (stage I/II) was observed for urinary HE4 
concentration  when compared to ratio of urinary HE4/
glomerular filtration rate (Figure 4).
Serum concentrations of human epidydimis secretory 
protein 4 disclosed higher diagnostic accuracy when 
compared to urinary concentration of HE4, but both 
of them were higher when compared to discriminatory 
accuracy of CA125 (Figure 5). At fixed specificity of 75% 
unchanged urinary human epidydimis secretory protein 4 
had sensitivity of 78.3% (at cutoff level of 13,000 pmol/l), 
but sensitivity of CA125 was only 47.8%.
Discussion
Hellström et al. have described higher urinary 
concentrations of HE4 in patients with early and late stage 
ovarian cancers (Hellstrom et al., 2010). Higher mean 
urinary HE4 concentrations in ovarian cancer patients 
were found also in our study population. 
It should be noted that urinary concentrations of human 
epidydimis secretory protein 4 concentrations may be 
affected by renal function, because glomerular filtration 
rate decreases with age (Davies et al., 1950). For that 
reason, older women with reduced glomerular filtration 
rate are expected to have lower HE4 concentration 
in urine, compared with patients whose glomerular 
filtration rate is normal. In our study, ratio of urinary 
HE4 concentration and glomerular filtration rate revealed 
higher diagnostic accuracy when compared to unchanged 
urinary levels of HE4 - area under the curves were 86.1% 
and 85.8%, respectively. When HE4/GFR was applied 
to discriminate patients with early stage ovarian cancer, 
unchanged HE4 was more accurate and discriminatory 
power more pronounced – AUC for HE4/GFR 0.602 
and 0.701 for unchanged concentrations of HE4. In the 
study of Hellström et al. ratio of urinary HE4 and urinary 
creatinine concentration was measured. They found that 
HE4/creatinine ratio had higher diagnostic accuracy in 
comparison to unchanged urinary HE4 concentration 
(Hellstrom et al., 2010). Findings of Hellstrom et al. study 
are conflicting to the data found in our study. Unchanged 
concentrations of urinary HE4 revealed higher accuracy 
min, respectively) in comparison to women in the control 
group (81.86±20.60 mL/min).
 Similarly, there was no difference in the mean urinary 
creatinine concentrations in (p=0.143), although there 
was tendency for higher urinary creatinine concentrations 
Ronalds Macuks et al
Asian Pacific Journal of Cancer Prevention, Vol 13, 20124698
when compared to HE4/creatinine ratio – AUC 0.970 vs. 
0.937. This can be explained by the model applied in the 
study of Hellstrom et al. – high accuracy was observed 
when a HE4/creatinine Combo model was applied. 
The particular HE4/creatinine Combo model has been 
calculated in the logistic regression analysis considering 
absolute concentration of HE4 and also HE4/creatinine 
ratio (Hellstrom et al., 2010). In the identification of 
early stage ovarian cancer Hellström et al. had higher 
diagnostic accuracy when compared to our study results 
- 70.1% vs. 96.9%. Diagnostic accuracy of urinary HE4 
in the identification of early stage ovarian cancer patients 
discovered by Hellstrom et al. is also higher in comparison 
to previously described HE4 diagnostic characteristics 
when analysed in serum (Hellstrom et al., 2010; Partheen 
et al., 2011). This can be explained with the fact that 
HE4/creatinine Combo model has been analyzed in the 
validation setting consisting of only 32 ovarian cancer 
patients with advanced stage ( stage III/IV) ovarian cancer 
(Hellstrom et al., 2010). Also higher diagnostic accuracy 
of early stage ovarian cancer comparatively to late stage 
ovarian cancer can be explained by using coefficients 
derived from logistic regression in the analysis of early 
stage ovarian cancer patients and healthy controls. 
When the accuracy of urinary HE4 was analyzed in 
the context of serum HE4 and CA125, higher diagnostic 
accuracy was observed for HE4 analyzed in sera, but the 
difference was not statistically significant, and that gives 
promising options for noninvasive detection of biomarker 
levels in the future.
It should be noted that the diagnostic potential of 
urinary human epidydimis secretory protein 4 has been 
analyzed only in some studies; therefore further trials 
with larger sample size are necessary to reveal clear 
conclusions.
In conclusions, Ovarian cancer patients have higher 
urinary concentrations of human epidydimis secretory 
protein 4 than patients with benign ovarian tumors. 
Urinary HE4 has comparable discriminatory accuracy 
with serum HE4 of benign and malignant ovarian tumors 
and can be recommended as non-invasive ovarian cancer 
risk assessment method. 
 
Acknowledgements 
Study was performed during PhD studies owing 
to project for PhD studies promotion in Latvia 
(P.Stradins University project number: 2009/0147/1DP/ 
1.1.2.1.2/09/IPIA/ VIAA/009) and Latvian University 
project for early cancer diagnostics (project number: 
2009/0220/1DP/1.1.1.2.0/09/APIA/VIAA/016). 
References
Boshell M, Lalani EN, Pemberton L ,et al (1992). The product 
of the human MUC1 gene when secreted by mouse cells 
transfected with the full-length cDNA lacks the cytoplasmic 
tail. Biochem Biophys Res Commun, 185, 1-8.
Davies DF, Shock NW (1950). Age changes in glomerular 
filtration rate, effective renal plasma flow, and tubular 
excretory capacity in adult males. J Clin Invest, 29, 496-507.
Drapkin R, von Horsten H, Lin Y, et al (2005). Human 
epididymis protein 4 (HE4) is a secreted glycoprotein 
that is overexpressed by serous and endometrioid ovarian 
carcinomas. Cancer Res, 65, 2162-9.
Guo L. Human epididymis protein 4 (HE4) plays a key role in 
ovarian cancer cells proliferation and motility. 2nd World 
Congress on Biomarkers & Clinical Research, 12-14 
September 2011, Baltimore Marriott Waterfront, USA.
Havrilesky LJ, Whitehead CM, Rubatt JM, et al (2008). 
Berchuck A. Evaluation of biomarker panels for early 
stage ovarian cancer detection and monitoring for disease 
recurrence. Gynecol Oncol, 110, 374-82. 
Hellstrom I, Heagerty PJ, Swisher EM, et al (2010). Detection 
of the HE4 protein in urine as a biomarker for ovarian 
neoplasms. Cancer Lett, 296, 43-8. 
Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al (2003). The 
HE4 (WFDC2) protein is a biomarker for ovarian cancer. 
Cancer Res, 63, 3695-3700. 
Huhtinen K, Suvitie P, Hiissa J, (2009). Serum HE4 concentration 
differentiates malignant ovarian tumours from ovarian 
endometriotic cysts. Br J Cancer, 100, 1315-9. 
Kirchhoff C, Osterhoff C, Pera I, Schröter S (1998). Function of 
human epididymal proteins in sperm maturation. Andrologia, 
30, 225-32.
Ligtenberg MJ, Kruijshaar L, Buijs F, et al (1992). Cell-
associated episialin is a complex containing two proteins 
derived from a common precursor. J Biol Chem, 267, 6171-7.
Moore R, Brown A, Miller M,et al (2008). The use of multiple 
novel tumor biomarkers for the detection of ovarian 
carcinoma in patients with a pelvic mass. Gynecol Oncol, 
108, 402-8.
Moore RG, Brown AK, Miller MC, et al (2008). The use of 
multiple novel tumor biomarkers for the detection of ovarian 
carcinoma in patients with a pelvic mass. Gynecol Oncol, 
108, 402-8. 
Partheen K, Kristjansdottir B, Sundfeldt K (2011). Evaluation 
of ovarian cancer biomarkers HE4 and CA-125 in women 
presenting with a suspicious cystic ovarian mass. J Gynecol 
Oncology, 22, 244-52. 
Rosen DG, Wang L, Atkinson JN, et al (2005). Potential markers 
that complement expression of CA125 in epithelial ovarian 
cancer. Gynecol Oncol, 99, 267-77.
Schummer M, Ng WV, Bumgarner RE, et al (1999).Comparative 
hybridization of an array of 21,500 ovarian cDNAs for the 
discovery of genes overexpressed in ovarian carcinomas. 
Gene, 238, 375-85.
Van Gorp T, Cadron I, Despierre E, et al (2011). HE4 and CA125 
as a diagnostic test in ovarian cancer: prospective validation 
of the risk of ovarian malignancy algorithm. Br J Cancer, 
104, 863-70. 
Yin BW, Lloyd KO (2001). Molecular cloning of the CA125 
ovarian cancer antigen: Identification as a new mucin, 
MUC16. J Biol Chem, 276, 27371-5.
